Intracerebral hemorrhage (ICH) is responsible for half of all stroke-related deaths but attracts only a fraction of the attention its better-known relative ischemic stroke gets. At Bioxodes, a clinical-phase biotech company, we faced a poignant consequence of this paradox when we struggled to recruit sufficient ICH patients into a clinical trial. Trial protocols are based largely on experiences with ischemic stroke patients, investigators noticed, which are very different from those with ICH. This real-life example underscores that not only is ICH a disease that needs better research funding, it also needs more public awareness.